Prior Authorization. Physician Name: Specialty: NPI Number: Physician Fax: Physician Phone: Physician Address: City, State, Zip:

Similar documents
Texas Standard Prior Authorization Form Addendum

2. Is the patient responding to medication? Y N

3. Does the patient meet ALL of the following requirements? Y N

2. Did the patient receive this medication during a recent hospitalization? Y N

2. Did the member receive this medication during a recent hospitalization? Y N

3. Has the member received the requested drug for less than 2 years? Y N

2. Is this request for a preferred medication? Y N

2. Does the member have a diagnosis of central precocious puberty? Y N

3. Has the member received the requested drug for less than 2 years? Y N

Pharmacy Prior Authorization

Pharmacy Prior Authorization

3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

2. Does the patient have chronic urticaria? Y N

3. Does the patient continue to receive nutritional or psychological counseling? Y N

Pharmacy Prior Authorization

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?

Circle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?

2. Does the patient have a diagnosis of Crohn s disease? Y N

Pharmacy Prior Authorization

2. Is the patient responding to Remicade therapy? Y N

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?

Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.

3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?

Pharmacy Prior Authorization

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

2. Does the patient have a diagnosis of giant cell arteritis (GCA)? Y N

3. Is the prescribed dose within the Food and Drug Administration (FDA)- approved dosing for giant cell arteritis?

Pharmacy Prior Authorization

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

3. Does the member continue to receive nutritional or psychological counseling?

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

Circle Yes or No Y N. [If yes, skip to question 29.] 2. Is the request for Sandostatin LAR? Y N. [If no, skip to question 5.] Prior Authorization

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]

1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Please submit supporting medical documentation, notes and test results.

Circle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Circle Yes or No Y N. [If no, then no further questions.]

Circle Yes or No Y N. [If yes, skip to question 13 REAUTHORIZATION REQUESTS]

[If yes, no further questions.]

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Circle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

Pharmacy Prior Authorization

Pharmacy Prior Authorization

Prior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:

2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Drug Name (specify drug) Quantity Frequency Strength

Drug Name (specify drug) Quantity Frequency Strength

Pharmacy Prior Authorization

Circle Yes or No Y N. [If yes, no further questions.]

Texas Prior Authorization Program Clinical Edit Criteria

2. Is the request for Humatrope? Y N [If no, skip to question 6.]

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Drug Name (specify drug) Quantity Frequency Strength

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Ribavirin (Medicare Prior Authorization)

Molina Healthcare of Texas

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Medications and Children Disorders

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

Calcitonin Gene Related Peptide Receptor Inhibitors Prior Authorization Criteria:

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

Steps for Initiating Electroconvulsive Therapy Treatment

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Antidepressant Prior Authorization Request

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN

Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist

Drug Use Evaluation: Low Dose Quetiapine

Carefirst. +.V Family of health care plans

REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form may be sent to us by mail or fax:

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

FLUOXETINE 60 MG oral tablet FLUOXETINE 90 MG oral delayed release (once weekly) capsule

Psychiatric Medications. Positive and negative effects in the classroom

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None

Section I. Short-acting opioid Prior Authorization Criteria

Quick Guide to Common Antidepressants-Adults

Transcription:

12/16/2015 Prior Authorization AETA BETTER HEALTH OF TEXAS MEDICAID Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Aetna Better Health of Texas Medicaid (Bexar and Tarrant) at 1-844-275-1084. Please contact Aetna Better Health of Texas Medicaid (Bexar) at 1-800-248-7767 or Aetna Better Health of Texas Medicaid (Tarrant) at 1-800-306-8612 with questions regarding the Prior Authorization process. When conditions are met, we will authorize the coverage of Antipsychotics (Medicaid). Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise. Drug ame (specify drug) Quantity Frequency Strength Route of Administration Expected Length of therapy Patient Information Patient ame: Patient ID: Patient Group o.: Patient DOB: Patient Phone: Prescribing Physician Physician ame: Specialty: PI umber: Physician Fax: Physician Phone: Physician Address: City, State, Zip: Diagnosis: ICD Code: Please circle the appropriate answer for each question. Question Circle es or o 1. Is the incoming claim for a first generation antipsychotic? [If yes, then skip to question 5.] 2. Is the patient less than 3 years of age? [If yes, then no further questions.] 3. Is the patient greater than 5 years of age? [If yes, then skip to question 5.]

Question 4. Is the incoming request for aripiprazole or risperidone (excluding long-acting preparations)? Circle es or o 5. Does the patient have a diagnosis of insomnia in the last 365 days? [If yes, then skip to question 8.] 6. Does the patient have a diagnosis of major depressive disorder (MDD) in the last 365 days? [If no, then skip to question 8.] 7. Does the patient have 1 claim for an antidepressant agent included in Table C (below) in the last 60 days? [If yes, then skip to question 9.] 8. Does the patient have a diagnosis included in Table A or Table B (below) in the last 730 days? 9. Does the patient have 2 or more active claims for different antipsychotic agents in the last 180 days (excluding the incoming request)? [If no, then skip to question 11.] 10. Does the patient have 2 or more active claims for different antipsychotic agents in the last 30 days with at least 30 days supply remaining (excluding the incoming request)? 11. Is this request for a non-preferred drug? The Texas Medicaid Preferred Drug List can be found at txvendordrug.com 12. Has the patient had a treatment failure with a preferred drug within any subclass or a contraindication or allergic reaction to any preferred drugs? If yes, PLEASE LIST which drug, dates tried, and describe treatment failure, contraindication or allergic reaction experienced.

Comments: I affirm that the information given on this form is true and accurate as of this date. Prescriber (Or Authorized) Signature Prescriber (Or Authorized) Signature Date Date Table A ICD-9 Code 295 SCHIZOPHREIC DISORDERS 296.0 BIPOLOAR I DISORDER, SIGLE MAIC EPISODE 296.4 BIPOLAR I DISORDER, MOST RECET EPISODE (OR CURRET) MAIC 296.5 BIPOLAR I DISORDER, MOST RECET EPISODE (OR CURRET) DEPRESSED 296.6 BIPOLOAR I DIOSRDER, MOST RECET EPISODE (OR CURRET) MIXED 296.7 BIPOLAR I DISORDER, MOST RECET EPISODE (OR CURRET) USPECIFIED 296.80 BIPOLAR DISORDER, USPECIFIED 296.89 OTHER BIPOLAR DISORDERS 299.0 AUTISTIC DISORDER 296.99 OTHER SPECIFIED EPISODIC MOOD DISORDER 307.23 TOURETTE S DISORDER ICD-10 Code F20 SCHIZOPHREIA F31.0 BIPOLAR DISORDER, CURRET EPISODE HPOMAIC F31.1 BIPOLAR DISORDER, CURRET EPISODE MAIC WITHOUT PSCHOTIC FEATURES F31.6 BIPOLAR DISORDER, CURRET EPISODE MIXED F31.81 BIPOLAR II DISORDER F31.9 BIPOLAR DISORDER, USPECIFIED F34.8 OTHER PERSISTET MOOD DISORDER F84.0 AUTISTIC DISORDER F95.2 TOURETTE S DISORDER

Table B ICD-9 Code 312.81 CODUCT DISORDER, CHILDHOOD OSET 312.82 CODUCT DISORDER, ADOLESCET OSET 312.89 CODUCT DISORDER, OSET USPECIFIED 297 DELUSIOAL DISORDERS 297.0 PARAOID STATE, SIMPLE 297.1 DELUSIOAL DISORDER 297.2 PARAPHREIA 297.3 SHARED PSCHOTIC DISORDER 297.8 OTHER SPECIFIED PARAOID STATES 297.9 USPECIFIED PARAOID STATE 296.90 USPECIFIED EPISODIC MOOD DISORDER 298.9 USPECIFIED PSCHOSIS 299 PERVASIVE DEVELOPMETAL DISORDERS 299.1 CHILDHOOD DISITEGRATIVE DISORDER 299.8 OTHER SPECIFIED PERVASIVE DEVELOPMETAL DISORDER 299.9 USPECIFIED PERVASIVE DEVELOPMETAL DISORDER 312.34 ITERMITTET EXPLOSIVE DISORDER 313.81 OPPOSITIOAL DEFIAT DISORDER F91.1 CODUCT DISORDER, CHILDHOOD-OSET TPE F91.2 CODUCT DISORDER, ADOLESCET-OSET TPE F91.9 CODUCT DISORDER, USPECIFIED F22 F39 F09 F29 DELUSIOAL DISORDERS USPECIFIED MOOD DISORDER USPECIFIED METAL DISORDER DUE TO KOW PHSIOLOGICAL CODITIO USPECIFIED PSCHOSIS OT DUE TO A SUBSTACE OR KOW PHSIOLOGICAL CODITIO F84.8 OTHER PERVASIVE DEVELOPMETAL DISORDERS F84.9 PERVASIVE DEVELOPMETAL DISORDER, USPECIFIED F63.81 ITERMITTET EXPLOSIVE DISORDER F91.3 OPPOSITIOAL DEFIAT DISORDER

Table C Required quantity: 1 Look back timeframe: 60 days APLEZI ER BRISDELLE BUPROPIO ER BUPROPIO BUPROPIO SR BUPROPIO XL CELEXA CITALOPRAM EFFEXOR EMSAM PATCH ESCITALOPRAM FLUOXETIE FLUVOXAMIIE FLUVOXAMIE ER FORFIVO XL KHEDEZLA ER MARPLA MIRTAZAPIE EFAZODOE OLEPTRO ER PAROXETIE PAROXETIE CR PAXIL PEXEVA PHEELZIE PRISTIQ ER PROZAC SERTRALIE TRALCPROMIE TRAZODOE VELAFAXIE VELAFAXIE ER VIIBRD WELLBUTRI WELLBUTRI SR ZOLOFT